Year: 2026

NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

Written by Customer Service on March 31, 2026. Posted in Earnings Releases And Operating Results.

Completed End-of-Phase 2 meeting with the FDA; Company expects to provide a regulatory update in early 2Q 2026 and remains on track to initiate a Phase 3 study in chronic tetraplegia in mid-2026. Company expects to present clinical data from independent, blinded biomechanical gait analyses of the CONNECT SCI study in 2Q 2026, providing additional evidence with the potential to further support the systemic biological effect of NVG-291, differentiating genuine neural recovery from compensatory movement. Company expects to expand NVG-291 into complementary clinical indications, as informed by established preclinical efficacy, with prioritization expected to be announced by mid-2026. Successful Nasdaq listing and continued growth of leadership team supports the Company’s emergence as a leader in the development of neuroreparative therapeutics.VANCOUVER,...

Cloudastructure Inc. Reaffirms Prior Guidance of Approximately 270% Year-Over-Year Revenue Growth and More Than $5.0 Million in Recognized Revenue in 2025; Rescheduling Fiscal Year 2025 Conference Call

Written by Customer Service on March 31, 2026. Posted in Public Companies.

PALO ALTO, Ca, March 31, 2026 (GLOBE NEWSWIRE) — Cloudastructure, Inc. (Nasdaq: CSAI) (“we,” “us,” “our,” “Cloudastructure” or the “Company”) an award-winning leader in AI Surveillance and Remote Guarding, today reaffirmed its prior guidance of approximately 270% year-over-year revenue growth and more than $5.0 million in recognized revenue in 2025. Due to a scheduling conflict the Company also plans to reschedule its previously announced conference call to discuss its fiscal year 2025 financial results. Cloudastructure will announce a new date and time for the conference call as soon as practicable. ABOUT CLOUDASTRUCTURE Headquartered in Palo Alto, California, Cloudastructure’s advanced award-winning security platform utilizes a scalable cloud-based architecture that features cloud video surveillance with proprietary, state-of-the-art...

Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

Written by Customer Service on March 31, 2026. Posted in Public Companies.

New Drug Application (NDA) for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations (microcystic LMs) on track for planned submission in second half of 2026 Accelerating U.S. launch readiness for QTORIN™ rapamycin for microcystic LMs; potential to become the first FDA-approved therapy and first-line, standard-of-care treatment for serious, lifelong disease affecting an estimated more than 30,000 diagnosed patients in the U.S. Initiation of Phase 3 trial of QTORIN™ rapamycin for the treatment of cutaneous venous malformations planned for second half of 2026 Initiation of Phase 2 trial of QTORIN™ rapamycin for the treatment of clinically significant angiokeratomas planned for second quarter of 2026 Initiation of Phase 2 trial of QTORIN™ pitavastatin for the treatment of disseminated...

BOS Reports Financial Results for the Fourth Quarter and Full Year 2025

Written by Customer Service on March 31, 2026. Posted in Public Companies.

Delivers Record Year Performance Provides Initial 2026 Revenue and Net Income Guidance RISHON LE ZION, Israel, March 31, 2026 (GLOBE NEWSWIRE) — BOS Better Online Solutions Ltd. (BOSC) today reported financial results for the fourth quarter and full-year ended December 31, 2025, including record revenue and profitability. Fourth Quarter 2025 Financial Highlights:Revenues$12.6M +21.5%Compared to $10.4M in Q4 2024 EBITDA$944K +32%Compared to $715K in Q4 2024Net Income$819K +68.9%Compared to $485K in Q4 2024 EPS$0.12 +50%Compared to $0.08 in Q4 2024Cash & Equivalent$11.8MAs of December 31, 2025 Contracted Backlog$24MAs of December 31, 2025Full Year 2025 Financial Highlights:Revenues$50.6M +26.6%Compared to $39.9M in 2024 EBITDA$4.6M +42.6%Compared to $3.2M in 2024Net Income$3.6M +57.0%Compared to $2.3M in 2024 EPS$0.59...

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

Written by Customer Service on March 31, 2026. Posted in Public Companies.

ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 patients annually in US/EU C-Further Consortium collaboration adds to growing non-dilutive funding for PRAME-TCR iNKT in pediatric oncology NIH STTR grant and Mary Gooze philanthropic award fully fund graft-versus-host disease (GVHD) preclinical data with clinical trial launch in 1H 2026 Keystone Symposia data report iNKT depletion in end-stage Pulmonary Fibrosis (IPF); underscores pipeline expansion Portfolio focused on high-value immune restoration with multiple 2026 clinical catalystsNEW YORK, March 31, 2026 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune...

Hypercharge Announces Appointment of Kyle Moncrief, CFA as VP, Corporate Development and FP&A, and Changes to Board of Directors

Written by Customer Service on March 31, 2026. Posted in Public Companies.

New leadership appointment supports Hypercharge’s growth pipeline, strategic partnerships, and market outreach VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) — Hypercharge Networks Corp. (TSXV: HC; OTC: HCNWF; FSE: PB7) (the “Company” or “Hypercharge”), a leading, smart electric vehicle (EV) charging solutions provider and network operator, is pleased to announce the appointment of Kyle Moncrief, CFA, as Vice President, Corporate Development and Financial Planning & Analysis. In this role, Mr. Moncrief will lead corporate strategy, long-term planning, and enterprise value creation initiatives, with a focus on advancing strategic partnerships, supporting revenue growth initiatives, and strengthening Hypercharge’s capital markets outreach. Working closely with the Company’s executive leadership, he will help advance...

SAGA Metals Reports Assays from R-0021 to R-0023 with Intercepts Including 53.18% Fe₂O₃, 7.08% TiO₂, 0.414% V₂O₅ from 2026 Drilling at Trapper South, Radar Critical Minerals Project in Labrador

Written by Customer Service on March 31, 2026. Posted in Public Companies.

VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) — SAGA Metals Corp. (“SAGA” or the “Company”) (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H), a North American exploration company focused on critical mineral discoveries, is pleased to report additional assay results from drill holes R-0021, -0022 and -0023 completed in 2026 as part of its ongoing maiden Mineral Resource Estimate (“MRE”) diamond drill program at the Trapper Zone within the 100%-owned Radar Titanium-Vanadium-Iron Project near Cartwright, Labrador, Canada. Trapper South Assay HighlightsAnalytical results received for three (3) additional diamond drill holes (R-0021 to R-0023) from the MRE drill program reinitiated in 2026, delivering consistent broad intercepts of oxide mineralization. Key intercepts include:Hole R-0021:...

InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium

Written by Customer Service on March 31, 2026. Posted in Public Companies.

JENA, Germany, March 31, 2026 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Raymond James 2026 Biotech Innovation Symposium. Details are as follows: Raymond James 2026 Biotech Innovation SymposiumApril 14, 2026, in New York, NYThe Company will hold one-on-one investor meetings. About InflaRxInflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory...

Rio Silver Closes $3.0M Private Placement with Eric Sprott as Lead Investor

Written by Customer Service on March 31, 2026. Posted in Public Companies.

VANCOUVER, British Columbia , March 31, 2026 (GLOBE NEWSWIRE) — Rio Silver Inc. (the “Company” or “Rio Silver”) (TSX.V: RYO) (OTC: RYOOF) is pleased to announce that it has closed its non-brokered private placement (the “Offering”), previously announced on February 25, 2026, by issuing an aggregate of 8,571,429 units (the “Units”) of the Company at a price of $0.35 per Unit for gross proceeds of $3,000,000. Each Unit is comprised of one common share of the Company and one-half of a common share purchase warrant (each whole warrant, a “Warrant”), with each Warrant exercisable to purchase an additional common share of the Company at a price of $0.50 per common share for a period of 24 months from the date of issue, subject to early expiry in the event that the closing price of the common...

AGA Precision Systems Signs Long-Term Agreement to Supply Mission-Critical Aerospace and Defense Components to Turbo-Jet Products

Written by Customer Service on March 31, 2026. Posted in Public Companies.

NEWPORT BEACH, Calif., March 31, 2026 (GLOBE NEWSWIRE) — AGA Precision Systems LLC (“AGA”), a precision aerospace manufacturing company and wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), today announced the execution of a Long-Term agreement (“LTA”) with Turbo-Jet Products Co., Inc. (“Turbo-Jet Products”), a California-based aerospace and defense supplier. Under the terms of the LTA, AGA will supply mission-critical aerospace and defense components in support of Turbo-Jet Products’ commercial and defense programs. The LTA provides an agreement framework that governs all future purchase orders issued during the LTA’s term. The LTA includes an initial five-year term, with provisions for annual renewals, supporting a long-term strategic supply relationship between the parties. Strategic Importance The company believes...

Year: 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals